The question behind the search is almost always the same: someone has a tendon, ligament or gut problem, has read that both of these help, and wants to know which one to run — or whether to run both. The honest answer starts somewhere less satisfying than a pick. Both compounds sit at the same evidence tier on this site, and the reasons they sit there are completely different. That difference is more useful to understand than any ranking would be.
| BPC-157 | TB-500 | |
|---|---|---|
| Evidence tier | Preclinical onlyAnimal or mechanistic data plus community convention. No meaningful human evidence for the use discussed. | Preclinical onlyAnimal or mechanistic data plus community convention. No meaningful human evidence for the use discussed. |
| Regulatory status | Not approved for human use | Not approved for human use |
| Researched for | Tissue repair across tendon, ligament and gut models. One of the most-studied compounds in the field — but nearly all of it in animals. | The research form of thymosin β-4 — wound healing, blood-vessel formation and tissue remodelling. |
| What people use it for | Accelerated healing of tendons, ligaments, muscle, and joint injuries; reduced chronic pain and inflammation; improvements in gut issues. | Accelerated soft-tissue healing (tendons, ligaments, muscles); reduced inflammation and joint pain; improved flexibility and range of motion. |
| Reported figure | 10 mg vial + 2 mL water = 5,000 mcg/mL 500 mcg → 0.10 mL · 10 unitsOne reported reference at that reconstitution — not a standard. | 10 mg vial + 2 mL water = 5,000 mcg/mL 1 mg → 0.20 mL · 20 unitsOne reported reference at that reconstitution — not a standard. |
| Route | Injected subcutaneously by convention. The one human efficacy trial was oral. | Injected subcutaneously by convention. The human trials of the parent molecule were intravenous or eye drop. |
| Calculator entry | Yes — BPC-157 calculator | Yes — TB-500 calculator |
Scroll the table sideways →
Both compounds are graded preclinical only here, and neither is approved for human use. That is where the similarity ends.
BPC-157's gap is a volume problem. This site grades it “one of the most-studied compounds in the field — almost entirely in rats. The only human efficacy RCT (PL 14736) was ORAL, for ulcerative colitis, at doses far below what people inject. Two or three small human safety pilots exist; none were dose-finding.” So there is a real literature, and it mostly does not describe what people are doing with the vial.
TB-500's gap is a molecule problem, and it is the sharper of the two. It is “the clearest case of trial data belonging to a different molecule. All human trials (RegeneRx) used FULL-LENGTH thymosin beta-4 by IV or eye drop. TB-500 is a synthetic fragment, injected subcutaneously, with zero human dose-ranging trials of its own.” Trials cited in TB-500's favour are frequently not trials of TB-500.
Neither, in other words, has human evidence for the injected use — this is not a case where one has real trials and the other doesn't.
On stacking: the two are routinely run together, and the site's KLOW blend pairs both with GHK-Cu and KPV. What's known about the combination is nothing. No trial has tested it. Each component carries its own evidence, and blending them does not add any — it just makes the source of any effect, or any side effect, impossible to attribute.
Education only. This page is educational. Most compounds referenced are not approved for human use, and a "research use only" label carries no legal status of its own.
A comparison, not a recommendation. Nothing on this page ranks one compound above another or suggests running either. Where a figure appears, it is one reported reference at the reconstitution shown — not a standard, not a clinical dose.
Reference ranges. Any amounts mentioned are values commonly reported in published research and community protocols, provided for reference only. Reported does not mean established, safe, or effective.
Not medical advice. Nothing here constitutes medical advice, diagnosis, or treatment. Several of these are prescription medicines in Canada and the US, and several are approved nowhere at all. Consult a qualified healthcare professional before beginning any protocol.